Drug-induced hypo- and hyperprolactinemia: mechanisms, clinical and therapeutic consequences. - Wikidata - awgldk - TriplyDB

Drug-induced hypo- and hyperprolactinemia: mechanisms, clinical and therapeutic consequences.

Drug-induced hypo- and hyperprolactinemia: mechanisms, clinical and therapeutic consequences.

http://www.wikidata.org/entity/Q38100267

about

Current Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive Review The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.Circulating levels of hormones, lipids, and immune mediators in post-traumatic stress disorder - a 3-month follow-up study.Aripiprazole-induced Hyperprolactinemia in a Young Female with Delusional Disorder Challenges and pitfalls in the diagnosis of hyperprolactinemia.Pharmacogenetics of second-generation antipsychotics.Adjunctive metformin for antipsychotic-related hyperprolactinemia: A meta-analysis of randomized controlled trials.Neuroendocrine Regulation of Anxiety: Beyond the Hypothalamic-Pituitary-Adrenal Axis.Prevalence and risk factors of hyperprolactinemia among patients with various psychiatric diagnoses and medications.Effect of Peony-Glycyrrhiza Decoction on Amisulpride-Induced Hyperprolactinemia in Women with Schizophrenia: A Preliminary Study.Plasma Oxytocin Level and Sexual Dysfunction in Depressed Women Treated by Either Fluoxetine or Citalopram: a Pilot Clinical Trial.Management of prolactinoma: a survey of endocrinologists in China

P2860

Q28079821-77A02BE3-95C4-4C57-B93B-BA59804FFAC9 Q33619940-419E0AC9-1E78-4998-AFA6-8AD5F3E79CD4 Q35403873-BB7F51FB-8A49-4D07-9E6E-0FED56C39C9A Q36997248-91C92AA5-BF77-4ABB-A3D3-0C585461ECA2 Q38204249-AD37529D-CAAC-427D-9B98-6D40FC76F56A Q38217628-36837A65-57C5-466D-BE12-F8F4BAF1596B Q38858121-A4C7884A-2E50-40A7-AE17-5F3A4A2E0B3D Q38869219-A4499B32-F003-401C-8098-B8D4A07DFD28 Q47555827-DE7C5B9A-D260-4742-ADC6-375822CE8441 Q47556007-76C7247F-77E1-4866-8C43-0ECF54F3E241 Q55039715-A22357C3-0294-4F03-892F-BB9AC038E5DA Q57818917-884D6DCB-C352-4E3A-9884-557CF2902AC0

P2860

Drug-induced hypo- and hyperprolactinemia: mechanisms, clinical and therapeutic consequences.

http://www.wikidata.org/entity/Q38100267

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Drug-induced hypo- and hyperpr ...... and therapeutic consequences.

@en

type

label

Drug-induced hypo- and hyperpr ...... and therapeutic consequences.

@en

prefLabel

Drug-induced hypo- and hyperpr ...... and therapeutic consequences.

@en

P1433

Q38100267-72142EAD-843B-4DC9-8BD4-3DB31C31750C

P1476

Q38100267-AE365F63-EC03-4E9A-BB4C-3671CAB4F9C4

P2093

Q38100267-094ABE71-C562-442B-8239-CBAB1860F115

Q38100267-6DBEADA5-A7D2-4786-9F77-0821C2FEA67C

Q38100267-B2376A8B-9BB5-4C86-A3C3-24D68A48D105

Q38100267-CDF681EF-FFF5-413A-8D18-5962697AFE33

P2860

Q38100267-00E013CC-6A3A-48D9-B674-5B4C43C2C35E

Q38100267-016355B9-2790-4D63-B08D-7AF0373DC301

Q38100267-031A9E14-4A25-406B-9F1E-90897A1B3F61

Q38100267-03BD4202-D7C5-4C82-B8A9-277927086A62

Q38100267-0FB33192-3268-46D0-BAD8-831EDDDDB5EA

Q38100267-155BA765-4BAA-48F3-A21B-B30082FA4E66

Q38100267-1762B8D6-12E6-4F5D-9F9F-ADF0D64027A2

Q38100267-19BE973C-7BE2-4B9A-9352-4F47D2711223

Q38100267-1DE9149B-7F77-4C7A-BCF6-43B5E0DB9AD4

Q38100267-21AD7273-8E18-47D9-AFEC-242CB1D1D838

P304

Q38100267-247C7847-CE7F-4849-BE90-8E4EF51B24EE

P31

Q38100267-50F86F70-AD92-4F76-A1E8-A813A4A9624A

P356

Q38100267-F3999D93-098D-4916-9AAB-CA5F530D4FB9

P407

Q38100267-D86ED29F-382D-4716-98B0-F8EDBA625527

P433

Q38100267-399D7DF3-B039-403F-8A3B-A78A0B9EC667

P478

Q38100267-E6DEA6AA-B936-40E0-94D1-469E76E9B738

P577

Q38100267-1798B49D-7A71-4EAB-9FC9-014723986A94

P698

Q38100267-A730FDE9-35CF-4B8F-921F-7F1634DE32A2

P356

17425255.2013.791283

P1433

Expert Opinion on Drug Metabolism & Toxicology

P1476

Drug-induced hypo- and hyperpr ...... and therapeutic consequences.

@en

P2093

Andrei Medvedovici

http://www.w3.org/2001/XMLSchema#string

Aurelian Emil Ranetti

http://www.w3.org/2001/XMLSchema#string

Flavian Ştefan Rădulescu

http://www.w3.org/2001/XMLSchema#string

Victor Voicu

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular mechanisms of prolactin and its receptor

Coherent view of non-Hodgkin's lymphoma

The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements

Prolactin, psychological stress and environment in humans: adaptation and maladaptation.

The risk for breast cancer is not evidently increased in women with hyperprolactinemia.

Lipophilicity in PK design: methyl, ethyl, futile.

Property-based design: optimization of drug absorption and pharmacokinetics.

Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.

Medication-induced hyperprolactinemia.

Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors.

P304

955-968

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/17425255.2013.791283

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23600946

http://www.w3.org/2001/XMLSchema#string